Q1FY27 revenues declined 6% YoY to ₹80.7 billion, mainly due to lower Lenalidomide sales and a semaglutide API provision, but base business showed strong double-digit growth. Gross margin and profit fell YoY, while sequential performance improved. Key launches and strategic appointments supported future growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.